Dr. Rick Panicucci, a director nominee, has served as Senior Vice President at BridgeBio from May 2018 to June 2023, before being promoted to Chief Technology Officer in July 2023. From February 2015 to April 2018, Dr. Panicucci served as the Vice President of Pharmaceutical Development at WuXi AppTec, where he was responsible for providing scientific leadership in the areas of Developability, Formulation Development and GMP Manufacturing. Prior to that, Dr. Panicucci served as the Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from January 2004 to February 2015, where he led the development and implementation of innovative dosage form designs and novel drug delivery technologies. He has also held positions as the Director of Formulation Development at Vertex Pharmaceuticals and Senior Scientist at Biogen. He earned a Bachelor of Science degree in Chemistry from McMaster University, a PhD in Chemistry from the University of Toronto and a post-doctoral fellowship at the University of California, Santa Barbara. We believe Dr. Panicucci’s experiences and education qualify him to serve as a member of our board of directors.